English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, September 12, 2023
中国抗体SM17新药研究申请再获国家药监局批准
中國抗體SM17新藥研究申請再獲國家藥監局批准
SinoMab's IND Application of SM17 has once again Received Approval from NAMP
Monday, August 14, 2023
中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准
中國抗體SM17針對治療哮喘疾病的新藥研究申請獲國家藥監局批准
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP
Monday, June 12, 2023
中国抗体SM17再增一项适应症研究申请 针对治疗特应性皮炎(AD)的新药研究申请获国家药监局药品审评中心受理
中國抗體SM17再增一項適應症研究申請 針對治療特應性皮炎(AD)的新藥研究申請獲國家藥監局藥品審評中心受理
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE
Monday, May 22, 2023
中国抗体SM17针对治疗哮喘的新药研究申请获国家药监局药品审评中心受理

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575